{"id":19863,"date":"2024-12-24T05:23:23","date_gmt":"2024-12-24T04:23:23","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/12\/24\/profiling-multiple-cd8-t-cell-functional-dimensions-enhances-breast-cancer-immune-assessment\/"},"modified":"2024-12-24T05:23:23","modified_gmt":"2024-12-24T04:23:23","slug":"profiling-multiple-cd8-t-cell-functional-dimensions-enhances-breast-cancer-immune-assessment","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/12\/24\/profiling-multiple-cd8-t-cell-functional-dimensions-enhances-breast-cancer-immune-assessment\/","title":{"rendered":"Profiling Multiple CD8+ T-Cell Functional Dimensions Enhances Breast Cancer Immune Assessment"},"content":{"rendered":"<div>\n<p>Cancer Immunol Res. 2024 Dec 23. doi: 10.1158\/2326-6066.CIR-24-0235. Online ahead of print.<\/p>\n<p>ABSTRACT<\/p>\n<p>CD8+ T-cell abundance is insufficient to assess antitumor immunity and shows poor performance in predicting breast cancer prognosis and immunotherapy response, presumably owing to the complexity of CD8+ T-cell functionalities. While single-cell RNA sequencing (scRNA-seq) can dissect the multifaceted functions of CD8+ T cells for better immune assessment, its clinical application is limited. Herein, we developed bulk RNA-seq-based FuncDimen models from integrative analysis of scRNA-seq and matched bulk RNA-seq data, to evaluate CD8+ T-cell functionalities across 5 dimensions: tumor reactivity, cytotoxicity, IFN-\u03b3 secretion, proliferation, and apoptosis. The FuncDimen models quantifying different functional dimensions of CD8+ T cells were validated in our breast cancer cohort and external databases using immunofluorescence and imaging mass cytometry. We calculated the FuncAggre score by weighted aggregation of all 5 FuncDimen models to encapsulate the overall antitumor immunity. In our breast cancer cohort and external databases, FuncAggre score demonstrated superior predictive performance for breast cancer prognosis (time-dependent area under the curve [AUC]: 0.56-0.70) and immunotherapy response (AUC: 0.71-0.83) over other immune biomarkers, regardless of the breast cancer molecular subtype. Together, the FuncDimen models offer a refined assessment of antitumor immunity mediated by CD8+ T cells in the clinic, enhancing prognostic prediction and aiding personalized immunotherapy in breast cancer.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39715293\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20241223232322&amp;v=2.18.0.post9+e462414\">39715293<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-0235\">10.1158\/2326-6066.CIR-24-0235<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2024 Dec 23. doi: 10.1158\/2326-6066.CIR-24-0235. Online ahead of print. ABSTRACT CD8+ T-cell abundance is insufficient to assess antitumor immunity and shows poor performance in predicting breast cancer prognosis and immunotherapy response, presumably owing to the complexity of CD8+ T-cell functionalities. While single-cell RNA sequencing (scRNA-seq) can dissect the multifaceted functions of CD8+ &#8230; <a title=\"Profiling Multiple CD8+ T-Cell Functional Dimensions Enhances Breast Cancer Immune Assessment\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2024\/12\/24\/profiling-multiple-cd8-t-cell-functional-dimensions-enhances-breast-cancer-immune-assessment\/\" aria-label=\"Read more about Profiling Multiple CD8+ T-Cell Functional Dimensions Enhances Breast Cancer Immune Assessment\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-19863","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=19863"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19863\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=19863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=19863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=19863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}